RenovoRx

10/12/2026

CEO Shaun Bagai spoke with Medtech Mentor Podcast's Crystal Howell about his MedTech journey, key lessons, and passion for innovative therapies that maximize patient impact.

He also highlights RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform, enabled by the FDA-cleared RenovoCath® device, and its potential to reshape treatment for difficult-to-treat tumors like pancreatic cancer.

Watch the full conversation: https://bit.ly/4ASAgeH

What does a back injury in high school, a Stanford pig lab, and a c...

10/08/2026

"For patients with borderline resectable pancreatic cancer, treatment before surgery can influence both whether surgery is possible and how completely the tumor can be removed," said Conor O'Neill, MD, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, and principal investigator of PRISM-TAMP. Read more: https://bit.ly/4rPiKDM

10/07/2026

“Enrolling the first PRISM-TAMP patient marks an important step for our IIT program as it moves from concept to clinical execution,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. PRISM-TAMP, sponsored by the University of Vermont, is the first RenovoRx supported investigator-initiated trial to advance to patient enrollment. Learn more: https://bit.ly/4rPiKDM

10/07/2026

RenovoRx announced the first patient enrolled in PRISM-TAMP, “PDAC Regression and Intraoperative Surgical Margin with Neoadjuvant TAMP,” an investigator-initiated trial (IIT) sponsored by the University of Vermont. One week after the IIT began, a second patient is also progressing toward TAMP treatment.

PRISM-TAMP is evaluating approved gemcitabine delivered via RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) platform, enabled by RenovoCath®, as neoadjuvant treatment before surgery for borderline Pancreatic Ductal Adenocarcinoma. Learn more: https://bit.ly/4rPiKDM

10/05/2026

"This innovative approach to delivering cancer treatment not only has the potential to improve outcomes for our patients but also preserve their quality of life, which is our ultimate goal," shared Joe K. Khoury, DO, MBA, an interventional radiologist at Winship Cancer Institute of Emory University and assistant professor in the Department of Radiology and Imaging Sciences at Emory University School of Medicine. Read more: https://bit.ly/46PO3ot

10/02/2026

"Locally advanced pancreatic cancer remains one of the most difficult cancers to treat, and patients have limited options when standard systemic therapies, like intravenous chemotherapy, are no longer effective,” said Gregory Tiesi, MD, FACS, FSSO, Chief of Surgical Oncology for the Southern Region and Medical Director of Hepatobiliary Surgery at Hackensack Meridian Health Jersey Shore University Medical Center, and lead author of the case series. Read more: https://bit.ly/3TEy09U

10/01/2026

“Independent, peer-reviewed publications such as this case series provide important clinical evidence supporting the potential of our novel, targeted drug-delivery approach,” Dr. Agah, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder, comments on the recently published peer-reviewed case series in Case Reports in Oncology. Learn more: https://bit.ly/3TEy09U

10/01/2026

RenovoRx announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center. The case series reports tumor treatment response, significant tumor marker reduction, and changes on imaging after treatment with the Trans-Arterial Micro-Perfusion (TAMP™) platform in patients with unresectable locally advanced pancreatic cancer. For more information: https://bit.ly/3TEy09U

09/28/2026

RenovoRx is pleased that institutions like Winship Cancer Institute of Emory University and Emory University Hospital are adopting our innovative, targeted drug-delivery approach for patients with . The approach uses our patented Trans-Arterial Micro-Perfusion (TAMP™) platform, enabled by the RenovoCath® device.

TAMP delivers therapeutic agents near the tumor site, with the potential to reduce toxicities associated with systemic chemotherapy and improve patient outcome and quality of life.

Together, we are advancing the future of cancer care. https://bit.ly/46PO3ot

09/14/2026

Reminder: CEO Shaun Bagai and CFO Mark Voll will present at the H.C. Wainwright 28th Annual Global Investment Conference today, September 14th at 1:30 pm ET. For webcast details, visit: https://bit.ly/4gy3Y0s